NASDAQ:TENX - Tenax Therapeutics Stock Price, News & Analysis

$1.13
-0.03 (-2.59 %)
(As of 08/19/2019 04:00 PM ET)
Today's Range
$1.12
Now: $1.13
$1.20
50-Day Range
$1.16
MA: $1.33
$1.55
52-Week Range
$1.03
Now: $1.13
$6.39
Volume40,800 shs
Average Volume585,714 shs
Market Capitalization$7.00 million
P/E RatioN/A
Dividend YieldN/A
Beta1.4
Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TENX
CUSIPN/A
Phone919-855-2100

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.10 per share

Profitability

Net Income$-6,810,000.00

Miscellaneous

Employees9
Market Cap$7.00 million
Next Earnings Date8/20/2019 (Estimated)
OptionableNot Optionable

Receive TENX News and Ratings via Email

Sign-up to receive the latest news and ratings for TENX and its competitors with MarketBeat's FREE daily newsletter.


Tenax Therapeutics (NASDAQ:TENX) Frequently Asked Questions

What is Tenax Therapeutics' stock symbol?

Tenax Therapeutics trades on the NASDAQ under the ticker symbol "TENX."

When did Tenax Therapeutics' stock split? How did Tenax Therapeutics' stock split work?

Tenax Therapeutics's stock reverse split on Monday, February 26th 2018. The 1-20 reverse split was announced on Friday, February 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 23rd 2018. An investor that had 100 shares of Tenax Therapeutics stock prior to the reverse split would have 5 shares after the split.

When is Tenax Therapeutics' next earnings date?

Tenax Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August 20th 2019. View Earnings Estimates for Tenax Therapeutics.

Has Tenax Therapeutics been receiving favorable news coverage?

News articles about TENX stock have been trending negative this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Tenax Therapeutics earned a news impact score of -2.3 on InfoTrie's scale. They also assigned news coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Tenax Therapeutics.

Are investors shorting Tenax Therapeutics?

Tenax Therapeutics saw a decline in short interest in July. As of July 31st, there was short interest totalling 151,100 shares, a decline of 29.0% from the June 30th total of 212,700 shares. Based on an average daily volume of 95,600 shares, the days-to-cover ratio is currently 1.6 days. Approximately 13.0% of the shares of the company are sold short. View Tenax Therapeutics' Current Options Chain.

Who are some of Tenax Therapeutics' key competitors?

What other stocks do shareholders of Tenax Therapeutics own?

Who are Tenax Therapeutics' key executives?

Tenax Therapeutics' management team includes the folowing people:
  • Mr. Anthony A. DiTonno, CEO & Director (Age 71)
  • Mr. Michael B. Jebsen, Pres & CFO (Age 48)
  • Ms. Nancy J. M. Hecox, Exec. VP of Legal Affairs, Gen. Counsel & Corp. Sec.
  • Maria Isabel Tomargo, Assistant VP of Marketing & Sales
  • Mr. Robert F. Diegelmann, Head of New Wound Care Division

Who are Tenax Therapeutics' major shareholders?

Tenax Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (5.80%) and Susquehanna International Group LLP (0.35%). View Institutional Ownership Trends for Tenax Therapeutics.

Which major investors are buying Tenax Therapeutics stock?

TENX stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Susquehanna International Group LLP. View Insider Buying and Selling for Tenax Therapeutics.

How do I buy shares of Tenax Therapeutics?

Shares of TENX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Tenax Therapeutics' stock price today?

One share of TENX stock can currently be purchased for approximately $1.13.

How big of a company is Tenax Therapeutics?

Tenax Therapeutics has a market capitalization of $7.00 million. The specialty pharmaceutical company earns $-6,810,000.00 in net income (profit) each year or ($9.04) on an earnings per share basis. Tenax Therapeutics employs 9 workers across the globe.View Additional Information About Tenax Therapeutics.

What is Tenax Therapeutics' official website?

The official website for Tenax Therapeutics is http://www.tenaxthera.com/.

How can I contact Tenax Therapeutics?

Tenax Therapeutics' mailing address is ONE COPLEY PARKWAY SUITE 490, MORRISVILLE NC, 27560. The specialty pharmaceutical company can be reached via phone at 919-855-2100 or via email at [email protected]


MarketBeat Community Rating for Tenax Therapeutics (NASDAQ TENX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  120 (Vote Outperform)
Underperform Votes:  79 (Vote Underperform)
Total Votes:  199
MarketBeat's community ratings are surveys of what our community members think about Tenax Therapeutics and other stocks. Vote "Outperform" if you believe TENX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TENX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel